Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 361

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial

Open access
Schoenfeld, Jonathan D., Hanna, Glenn J., Jo, Vickie Y., Rawal, Bhupendra, Chen, Yu-Hui, Catalano, Paul S., Lako, Ana, Ciantra, Zoe, Weirather, Jason L., Criscitiello, Shana, Luoma, Adrienne, Chau, Nicole, Lorch, Jochen, Kass, Jason I., Annino, Donald, Goguen, Laura, Desai, Anupam, Ross, Brendan, Shah, Hina J., Jacene, Heather A., Margalit, Danielle N., Tishler, Roy B., Wucherpfennig, Kai W., Rodig, Scott J., Uppaluri, Ravindra, Haddad, Robert I.·2020·JAMA Oncology

Abstract

Importance: Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and combining programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitors are 2 strategies to enhance antitumor immune responses that could be of benefit. Design, Setting, and Participants: In this randomized phase 2 clinical trial conducted at 1 academic center, 29 patients with untreated squamous cell carcinoma of the oral cavity (≥T2, or clinically node positive) were enrolled between 2016 to 2019. Interventions: Treatment was administered with nivolumab, 3 mg/kg, weeks 1 and 3, or nivolumab and ipilimumab (ipilimumab, 1 mg/kg, given week 1 only). Patients had surgery 3 to 7 days following cycle 2. Main Outcomes and Measures: Safety and volumetric response determined using bidirectional measurements. Secondary end points included pathologic and objective response, progression-free survival (PFS), and overall survival. Multiplex immunofluorescence was used to evaluate primary tumor immune markers. Results: Fourteen patients were randomized to nivolumab (N) and 15 patients to nivolumab/ipilimumab (N+I) (mean [SD] age, 62 [12] years; 18 men [62%] and 11 women [38%]). The most common subsite was oral tongue (n = 16). Baseline clinical staging included patients with T2 (n = 20) or greater (n = 9) T stage and 17 patients (59%) with node-positive disease. Median time from cycle 1 to surgery was 19 days (range, 7-21 days); there were no surgical delays. There were toxic effects at least possibly related to study treatment in 21 patients, including grade 3 to 4 events in 2 (N), and 5 (N+I) patients. One patient died of conditions thought unrelated to study treatment (postoperative flap failure, stroke). There was evidence of response in both the N and N+I arms (volumetric response 50%, 53%; pathologic downstaging 53%, 69%; RECIST response 13%, 38%; and pathologic response 54%, 73%, respectively). Four patients had major/complete pathologic response greater than 90% (N, n = 1; N+I, n = 3). With 14.2 months median follow-up, 1-year progression-free survival was 85% and overall survival was 89%. Conclusions and Relevance: Treatment with N and N+I was feasible prior to surgical resection. We observed promising rates of response in both arms, supporting further neoadjuvant studies with these agents. Trial Registration: ClinicalTrials.gov Identifier: NCT02919683.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2020.2955

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 361

Metadata

Authors
Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y.-H., Catalano, P. S., Lako, A., Ciantra, Z., Weirather, J. L., Criscitiello, S., Luoma, A., Chau, N., Lorch, J., Kass, J. I., Annino, D., Goguen, L., Desai, A., Ross, B., Shah, H. J., Jacene, H. A., Margalit, D. N., Tishler, R. B., Wucherpfennig, K. W., Rodig, S. J., Uppaluri, R., & Haddad, R. I.
Venue
JAMA Oncology
Published
2020-10-01
Volume
6
Issue
10
Pages
1563
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3080936926
Cited by
361
References
25
FWCI
14.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2020.2955
The paper
Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y.-H., Catalano, P. S., Lako, A., Ciantra, Z., Weirather, J. L., Criscitiello, S., Luoma, A., Chau, N., Lorch, J., Kass, J. I., Annino, D., Goguen, L., Desai, A., Ross, B., Shah, H. J., . . . Haddad, R. I. (2020). Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.2955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.